AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$57.02 USD
+0.73 (1.30%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $57.03 +0.01 (0.02%) 7:58 PM ET
5-Strong Sell of 5 5
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.02 USD
+0.73 (1.30%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $57.03 +0.01 (0.02%) 7:58 PM ET
5-Strong Sell of 5 5
A Value C Growth C Momentum B VGM
Zacks News
Haemonetics (HAE) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) potential in its Plasma franchise.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
3 Top-Rated Momentum Stocks to Buy Using Driehaus Strategy
by Tirthankar Chakraborty
Stocks like AMN Healthcare Services (AMN), Earthstone Energy (ESTE) and Hanmi Financial (HAFC) have been selected as the momentum picks for the day using the Driehaus strategy.
3 Reasons Why AMN Healthcare (AMN) Is a Great Growth Stock
by Zacks Equity Research
AMN Healthcare (AMN) possesses solid growth attributes, which could help it handily outperform the market.
Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision
by Zacks Equity Research
Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.
Here's Why Investors Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) better-than-expected results and expanded Panther installed base.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints
by Zacks Equity Research
The strengthening of the rate of exchange for the U.S. dollar relative to other currencies has a negative impact on IDEXX's (IDXX) revenues.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
BD's (BDX) Latest Collaboration to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.
Boston Scientific (BSX) Signs Obsidio-Acquisition Agreement
by Zacks Equity Research
Boston Scientific's (BSX) latest acquisition will add the FDA-approved GEM technology to its interventional oncology and embolization portfolio.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) robust segmental performance and Cantel Medical buyout.
Abiomed's (ABMD) Impella Favored by Latest Study Result
by Zacks Equity Research
Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.
Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids
by Zacks Equity Research
With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.
Here's Why You Should Retain Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
West Pharmaceutical's (WST) Latest Investment to Boost Business
by Zacks Equity Research
West Pharmaceutical's (WST) minority investment is expected to aid in meeting patients' continuously evolving needs of ease of use and effective methods of medicine delivery.
Charles River (CRL) Business Hurt by Macro and FX Headwinds
by Zacks Equity Research
In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.
Zacks.com featured highlights include AMN Healthcare Services, Encore Wire and Global Ship
by Zacks Equity Research
AMN Healthcare Services, Encore Wire and Global Ship are part of Zacks Screen of the Week article.
Accuray (ARAY) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Despite solid Product revenues, Accuray (ARAY) reports an overall soft Q4 performance.
Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered
by Zacks Equity Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.
Zacks.com featured highlights include AMN Healthcare Services, Quanex Building Products, Sonoco and Super Micro Computer
by Zacks Equity Research
AMN Healthcare Services, Quanex Building Products, Sonoco and Super Micro Computer are part of Screen of the Week article.
3 Profitable Stocks to Buy on the Basis of Net Income Ratio
by Tirthankar Chakraborty
AMN Healthcare Services (AMN), Encore Wire (WIRE) and Global Ship Lease (GSL) have been selected as the top picks with a high net income ratio.
Wall Street Analysts Think AMN Healthcare (AMN) Could Surge 25%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for AMN Healthcare (AMN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.